{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T18:03:57Z","timestamp":1771956237879,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jfma.2019.07.028","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T16:43:43Z","timestamp":1566405823000},"page":"532-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P3","title":["Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin"],"prefix":"10.1016","volume":"119","author":[{"given":"Chi-Ching","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shui-Yi","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Liang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Heng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Te-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang-Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Wei","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2019.07.028_bib1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.bpg.2012.09.012","article-title":"Public health issues of hepatitis C virus infection","volume":"26","author":"Papatheodoridis","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jfma.2019.07.028_bib2","series-title":"Hepatitis C. WHO fact sheet 164","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.jfma.2019.07.028_bib3","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2019.07.028_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.vhri.2013.08.001","article-title":"Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection","volume":"3","author":"McEwan","year":"2014","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jfma.2019.07.028_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/jmv.2001","article-title":"Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan","volume":"65","author":"Yu","year":"2001","journal-title":"J Med Virol"},{"key":"10.1016\/j.jfma.2019.07.028_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.23976","article-title":"Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients","volume":"53","author":"Yu","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2019.07.028_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"Electronic address: easloffice@easloffice.eu, european association for the study of the liver. EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2019.07.028_bib8","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2019.07.028_bib9","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2019.07.028_bib10","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.07.028_bib11","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.07.028_bib12","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/sj.bjp.0701775","article-title":"Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine- sensetive (es)-nucleoside transporter","volume":"123","author":"Jarvis","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jfma.2019.07.028_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2893.2004.00490.x","article-title":"Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection","volume":"11","author":"Sulkowski","year":"2004","journal-title":"J Viral Hepatol"},{"key":"10.1016\/j.jfma.2019.07.028_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1572-0241.2005.40757.x","article-title":"Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon\/ribavirin","volume":"100","author":"Balan","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2019.07.028_bib15","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1478-3231.2006.01354.x","article-title":"Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response","volume":"26","author":"Hung","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2019.07.028_bib16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/liv.13082","article-title":"A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection","volume":"36","author":"Kao","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2019.07.028_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2019.07.028_bib18","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.07.028_bib19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3350\/cmh.2017.0070","article-title":"Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: a retrospective multi-institutional study","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jfma.2019.07.028_bib20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/hepr.13246","article-title":"Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: a nationwide multicenter study by the Japanese Red Cross Liver Study Group","volume":"49","author":"Akahane","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2019.07.028_bib21","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.07.028_bib22","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","article-title":"Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis","volume":"155","author":"Esteban","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2019.07.028_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2019.07.028_bib24","doi-asserted-by":"crossref","first-page":"15255","DOI":"10.1038\/srep15255","article-title":"Peginterferon alfa-2a plus weight-based or flat-dose ribavirin for treatment-na\u00efve hepatitis C virus genotype 2 rapid responders: a randomized trial","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2019.07.028_bib25","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3748\/wjg.v24.i13.1478","article-title":"Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir\/ribavirin for Japanese genotype 2 hepatitis C virus","volume":"24","author":"Yada","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jfma.2019.07.028_bib26","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jhep.2017.01.020","article-title":"Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals","volume":"66","author":"Prenner","year":"2017","journal-title":"J Hepatol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664619304139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664619304139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:40:20Z","timestamp":1760539220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664619304139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0929664619304139"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2019.07.028","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2019.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}